Boston Scientific Corporation — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited, consolidated U.S. GAAP results. Boston Scientific develops and sells medical devices globally.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net sales | $3.856 billion | $3.389 billion | +13.8% reported; +15.0% operational; +13.1% organic |
| Gross profit / margin | $2.648 billion / 68.7% | $2.349 billion / 69.3% | Margin down 0.6 percentage points |
| Operating income | $675 million | $552 million | +22.3% |
| Net income attributable to common stockholders | $495 million | $300 million | +65.0% |
| Diluted EPS | $0.33 | $0.21 | Up $0.12 |
| Adjusted net income attributable to common stockholders (non-GAAP) | $832 million | $673 million | +23.6%; adjusted diluted EPS $0.56 vs. $0.47 |
| Cash from operating activities | $164 million | $190 million | Down $27 million |
Sales growth reflected broad portfolio performance, strong execution and underlying market growth. Cardiovascular sales rose 15.9% to $2.445 billion; MedSurg sales rose 10.3% to $1.412 billion. Cardiology growth was led by WATCHMAN and electrophysiology products, including FARAPULSE. Neuromodulation organic sales declined 1.3%, primarily amid U.S. spinal cord stimulation pressure. Gross margin fell mainly due to inventory charges, period expenses and foreign exchange, partly offset by favorable product mix. SG&A and R&D increased in dollars but declined as a share of sales.
Liquidity, debt and cash flows
- Cash and cash equivalents were $2.329 billion at quarter-end, versus $865 million at December 31, 2023. Cash, including restricted cash, totaled $2.496 billion.
- Total debt was $10.619 billion, versus $9.102 billion at year-end; current debt obligations were $1.085 billion. The company issued €2.0 billion of senior notes, generating $2.145 billion net proceeds, used in part to repay notes due in March 2024 and intended in part to fund the Axonics acquisition.
- Investing cash outflow was $285 million, including $179 million of property, equipment and software purchases. Financing cash inflow was $1.569 billion, principally reflecting the bond issuance.
- The company reported $2.750 billion of available revolving-credit liquidity and no revolver or commercial-paper borrowings. It was compliant with its leverage covenant: actual ratio 2.08x versus a 3.75x limit. Debt incurred for Axonics was excluded from the covenant calculation as permitted by the agreement.
- Management said existing cash, operating cash generation, capital-market access and credit facilities should fund operations and commitments for the next 12 months and the foreseeable future.
Material developments, outlook and risks
- Axonics acquisition: The company agreed to acquire Axonics for $71 per share in cash, approximately $3.670 billion, with expected completion in the second half of 2024. On April 3, 2024, the FTC issued a Second Request for information, extending the antitrust review waiting period. Closing remains subject to regulatory review and customary conditions. If the deal is not completed under specified circumstances, the 2024 Eurobonds are subject to special mandatory redemption at 101% of principal plus accrued interest.
- Outlook: The filing does not provide a clear numerical full-year sales or earnings guidance value. Management cited ongoing growth across much of the portfolio, while noting U.S. spinal cord stimulation pressure and continuing supply-chain, cost and foreign-exchange uncertainties.
- Tax: The effective tax rate declined to 18.9% from 29.4%, principally reflecting acquisition-related charges and discrete benefits for unrecognized tax benefits and stock compensation. Management noted potential future effects from global minimum-tax implementation and U.S. tax provisions scheduled to expire in 2025.
- Contingencies: Accrued legal matters totaled $283 million, down from $377 million at year-end; the company recorded no litigation-related net charges in the quarter. Litigation remains uncertain, including product-liability claims related to transvaginal mesh and a patent case involving Synergy stents in which a jury awarded $42 million; post-trial motions were pending. The company also disclosed government inquiries concerning alleged FCPA issues in Vietnam, its ambulatory ECG business and peripheral-intervention services through office-based labs.
- Other risks: Management cited supply availability and input-cost pressures, wage inflation, geopolitical conflict and trade restrictions, foreign-exchange exposure, reimbursement and regulatory changes, product acceptance, cybersecurity, litigation, and execution/integration risks for acquisitions and restructuring. The 2023 restructuring plan generated $3 million of restructuring charges and $43 million of related charges in Q1 2024.
Most important facts for investors to verify
- Whether the FTC review permits the Axonics acquisition to close on the expected timetable, and the financing and covenant consequences if it does not.
- Whether high reported sales growth translates into durable organic growth, particularly in electrophysiology, WATCHMAN, and the pressured U.S. neuromodulation business.
- Whether gross-margin pressure from inventory charges, expenses and currency moderates, and how cash conversion develops given lower operating cash flow.
- Debt levels, covenant headroom and the effect of acquisition funding; assess reported leverage alongside the permitted exclusion of $2.138 billion of Axonics-related debt.
- Developments in material litigation and government investigations, including potential cash costs beyond recorded legal accruals.